These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 19902320

  • 1. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH.
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [Abstract] [Full Text] [Related]

  • 2. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS.
    Diabetes Metab Res Rev; 2003 May; 19(6):487-93. PubMed ID: 14648808
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 4. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM.
    Biochem Biophys Res Commun; 2005 Oct 28; 336(3):747-53. PubMed ID: 16157299
    [Abstract] [Full Text] [Related]

  • 5. Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
    Guo Z, Qin Z, Zhang R, Li J, Yin Y.
    Eur J Pharmacol; 2012 Jun 15; 685(1-3):116-25. PubMed ID: 22542658
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
    Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS.
    J Pharmacol Exp Ther; 2006 Apr 15; 317(1):37-43. PubMed ID: 16368901
    [Abstract] [Full Text] [Related]

  • 7. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
    Rose M, Balakumar P, Singh M.
    Pharmacology; 2007 Apr 15; 80(2-3):177-84. PubMed ID: 17570955
    [Abstract] [Full Text] [Related]

  • 8. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J.
    Scand J Gastroenterol; 2009 Apr 15; 44(3):358-65. PubMed ID: 18991162
    [Abstract] [Full Text] [Related]

  • 9. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
    Baraka A, AbdelGawad H.
    J Cardiovasc Pharmacol Ther; 2010 Jun 15; 15(2):175-81. PubMed ID: 20133494
    [Abstract] [Full Text] [Related]

  • 10. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
    Geng DF, Wu W, Jin DM, Wang JF, Wu YM.
    Int J Cardiol; 2006 Oct 26; 113(1):86-91. PubMed ID: 16891009
    [Abstract] [Full Text] [Related]

  • 11. Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
    Iwamoto M, Hirohata S, Ogawa H, Ohtsuki T, Shinohata R, Miyoshi T, Hatipoglu FO, Kusachi S, Yamamoto K, Ninomiya Y.
    Hypertens Res; 2010 Dec 26; 33(12):1305-11. PubMed ID: 20944640
    [Abstract] [Full Text] [Related]

  • 12. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
    Liu DS, Liu WJ, Chen L, Ou XM, Wang T, Feng YL, Zhang SF, Xu D, Chen YJ, Wen FQ.
    Toxicology; 2009 Jun 16; 260(1-3):112-9. PubMed ID: 19464576
    [Abstract] [Full Text] [Related]

  • 13. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B.
    Arthritis Rheum; 2005 Mar 16; 52(3):759-69. PubMed ID: 15751073
    [Abstract] [Full Text] [Related]

  • 14. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice.
    Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Fulia F, Cuzzocrea E, Di Rosa M, Caputi AP, Thiemermann C.
    Crit Care Med; 2004 Feb 16; 32(2):457-66. PubMed ID: 14758164
    [Abstract] [Full Text] [Related]

  • 15. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
    Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I.
    J Am Coll Cardiol; 2004 Apr 21; 43(8):1481-8. PubMed ID: 15093887
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
    Zhang CH, Wen ZQ, Li JF, Li CZ, Shi M, Yang GW, Lan SM, Zhu Y, Wang F, Zhang YJ, Wang YY, Zhang H.
    Chin Med J (Engl); 2008 Jan 20; 121(2):166-71. PubMed ID: 18272045
    [Abstract] [Full Text] [Related]

  • 17. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
    Pelzer T, Jazbutyte V, Arias-Loza PA, Segerer S, Lichtenwald M, Law MP, Schäfers M, Ertl G, Neyses L.
    Biochem Biophys Res Commun; 2005 Apr 08; 329(2):726-32. PubMed ID: 15737646
    [Abstract] [Full Text] [Related]

  • 18. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, Doerries C, Horváth T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U.
    Circulation; 2007 Jul 10; 116(2):163-73. PubMed ID: 17592079
    [Abstract] [Full Text] [Related]

  • 19. Intra-coronary administration of soluble receptor for advanced glycation end-products attenuates cardiac remodeling with decreased myocardial transforming growth factor-beta1 expression and fibrosis in minipigs with ischemia-reperfusion injury.
    Lu L, Zhang Q, Xu Y, Zhu ZB, Geng L, Wang LJ, Jin C, Chen QJ, Schmidt AM, Shen WF.
    Chin Med J (Engl); 2010 Mar 05; 123(5):594-8. PubMed ID: 20367988
    [Abstract] [Full Text] [Related]

  • 20. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
    Yu X, Li C, Li X, Cai L.
    Toxicol Sci; 2007 Apr 05; 96(2):346-56. PubMed ID: 17264099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.